Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Scott Yaphe
AddedMar 31, 2024
UpdatedMay 31, 2026
Scott Yaphe

Scott Yaphe

Board Member, Hanger Network

CrunchbaseLinkedIn

Scott Yaphe's Career

Hanger Network
Hanger Network

New York City, NY, US

Board Member· Board
eXIthera Pharmaceuticals
eXIthera Pharmaceuticals

Westborough, MA, US

Board Member· Board
Censinet
Censinet

Boston, MA, US

Board Member· Board
Emerald Cloud Lab
Emerald Cloud Lab

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Scott Yaphe's Career

Hanger Network
Hanger Network
Series B$18M302005New York City, NY, US
Board Member· Board

Leadership at Hanger Network

Bob DavoliBob DavoliBoard Member
JD SchulmanJD SchulmanFounder
Jared D SchulmanJared D SchulmanBoard Member
eXIthera Pharmaceuticals
eXIthera Pharmaceuticals
Series B$18M302012Westborough, MA, US
Board Member· Board

Leadership at eXIthera Pharmaceuticals

William KosterWilliam KosterBoard Member
Neil HaywardNeil HaywardFounder
Fred MeyerFred MeyerBoard Member

Similar to eXIthera Pharmaceuticals

Anthos TherapeuticsAnthos TherapeuticsCambridge, MA, USBiopharmaceuticalsest. 2018Anthos TherapeuticsCambridge, MA, US · est. 2018

Anthos Therapeutics: Advancing CVM disease care through innovative, validated biopharmaceutical therapies.

Series A · $250M33
Initial TherapeuticsInitial TherapeuticsNew York City, NY, USMedicinesest. 2020Initial TherapeuticsNew York City, NY, US · est. 2020

Initial Therapeutics: An ATP company developing small-molecule medicines to prevent pathogenic protein synthesis.

Series A · $78.8M11
Exalys TherapeuticsExalys TherapeuticsSan Diego, CA, USDrugs, Therapeuticsest. 2018Exalys TherapeuticsSan Diego, CA, US · est. 2018

Exalys Therapeutics develops novel anti-inflammatory drugs, targeting diseases with limited treatments.

Series A · $15M32
TherapyxTherapyxBuffalo, NY, USBiotechnologyTherapyxBuffalo, NY, US

Buffalo-based TherapyX is a private biotech firm specializing in innovative development-stage solutions.

Seed · $2.8M11
Censinet
Censinet
Series A$19.3M442017Boston, MA, US
Board Member· Board

Leadership at Censinet

Eric YablonkaEric YablonkaBoard Member
Meg AranowMeg AranowBoard Member
Vin FabianiVin FabianiBoard Member
Ed GaudetEd GaudetCo-Founder
Stan NowakStan NowakBoard Member
Keith FiglioliKeith FiglioliBoard Member

Similar to Censinet

CynetCynetNew York City, NY, USSecurity, Threat Intelligenceest. 2015CynetNew York City, NY, US · est. 2015

Cynet: An Israel-born, Boston-based cybersecurity firm, specializing in threat intelligence and endpoint security.

Series C · $78M234
CyberSaintCyberSaintBoston, MA, USRisk Managementest. 2016CyberSaintBoston, MA, US · est. 2016

CyberSaint, Inc. provides a risk management platform enhancing cyber security and resilience.

Series A · $9M49
CensysCensysAnn Arbor, MI, USCybersecurity, Threat Intelligenceest. 2017CensysAnn Arbor, MI, US · est. 2017

Censys, a cybersecurity firm, offers asset discovery, risk monitoring, and threat analysis using its ASM platform.

Series B · $128.1M136
CynerioCynerioNew York City, NY, USSecurity Softwareest. 2017CynerioNew York City, NY, US · est. 2017

Cynerio: Ensuring data protection and patient safety through secure healthcare IoT solutions.

Series B · $37M79
Emerald Cloud Lab
Emerald Cloud Lab
Series C$92.1M1772010South San Francisco, CA, US
Board Member· Board

Leadership at Emerald Cloud Lab

Brian FrezzaBrian FrezzaCo-Founder
DJ KleinbaumDJ KleinbaumCo-Founder

Similar to Emerald Cloud Lab

BenchlingBenchlingSan Francisco, CA, USRD Platform, Softwareest. 2012BenchlingSan Francisco, CA, US · est. 2012

Benchling accelerates biotech R&D with its cloud-based collaboration platform.

Series F · $411.9M750
Luming LabsLuming LabsLowell, MA, USAI Software, Cloud Platformsest. 2023Luming LabsLowell, MA, US · est. 2023

LumingLabs: Democratizing cloud access with GPU-powered platforms for efficient AI and research management.

Series A · $400k5
MeentaMeentaBoston, MA, USCOVID Testing, Sequencingest. 2016MeentaBoston, MA, US · est. 2016

Meenta: A cloud-sequencing platform simplifying COVID-19 testing and scientific research logistics.

Pre-Seed · $2.2M7
Unchained LabsUnchained LabsPleasanton, CA, USLaboratory Equipmentest. 2015Unchained LabsPleasanton, CA, US · est. 2015

Unchained Labs, based in Pleasanton, US, provides innovative tools aiding researchers in real-world science.

Late Stage Private · $285M200

Scott Yaphe's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Scott Yaphe

Craig NankervisCraig NankervisBoard Member · Scale ComputingLaura WittLaura WittBoard Member · iZotopeMichael YangMichael YangBoard Member · Kiwi CrateJeff ReadyJeff ReadyBoard Member · CodeliciousPeter GyenesPeter GyenesBoard Member · RealPageScott RussellScott RussellBoard Member · SAP